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Background: We have established the critical role of ADA3 as a coactivator of estrogen receptor (ER), as well as its role
in cell cycle progression. Furthermore, we showed that ADA3 is predominantly nuclear in mammary epithelium, and
in ER+, but is cytoplasmic in ER- breast cancers, the latter correlating with poor survival. However, the role of nuclear
ADA3 in human mammary epithelial cells (hMECs), and in ER+ breast cancer cells, as well as the importance of
ADA3 expression in relation to patient prognosis and survival in ER+ breast cancer have remained uncharacterized.
Methods: We overexpressed ADA3 in hMECs or in ER+ breast cancer cells and assessed the effect on cell proliferation.
The expression of ADA3 was analyzed then correlated with the expression of various prognostic markers, as well as
survival of breast cancer patients.
Results: Overexpression of ADA3 in ER- hMECs as well as in ER+ breast cancer cell lines enhanced cell proliferation.
These cells showed increased cyclin B and c-MYC, decreased p27 and increased SKP2 levels. This was accompanied
by increased mRNA levels of early response genes c-FOS, EGR1, and c-MYC. Analysis of breast cancer tissue specimens
showed a significant correlation of ADA3 nuclear expression with c-MYC expression. Furthermore, nuclear ADA3 and
c-MYC expression together showed significant correlation with tumor grade, mitosis, pleomorphism, NPI, ER/PR status,
Ki67 and p27 expression. Importantly, within ER+ cases, expression of nuclear ADA3 and c-MYC also significantly
correlated with Ki67 and p27 expression. Univariate Kaplan Meier analysis of four groups in the whole, as well as the
ER+ patients showed that c-MYC and ADA3 combinatorial phenotypes showed significantly different breast cancer
specific survival with c-MYC-high and ADA3-Low subgroup had the worst outcome. Using multivariate analyses within
the whole cohort and the ER+ subgroups, the significant association of ADA3 and c-MYC expression with patients’
outcome was independent of tumor grade, stage and size, and ER status.
Conclusion: ADA3 overexpression enhances cell proliferation that is associated with increased expression of c-MYC.
Expression patterns with respect to ADA3/c-MYC can divide patients into four significantly different subgroups, with
c-MYC High and ADA3 Low status independently predicting poor survival in patients.
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Coordination of cell cycle progression with chromo-
somal duplication maintains genomic stability; a critical
cancer-associated trait [1]. Deregulated cell cycle com-
ponents have now also emerged as key biomarkers and
therapeutic targets in cancer [2]. Thus, a better under-
standing of cell cycle machinery and its aberrations in
cancer are of fundamental importance in cell and cancer
biology. Recently ADA3, a component of histone acetyl-
transferase (HAT) complexes, has emerged as a key
regulator of cell cycle progression through G1/S and
G2/M transitions and in maintaining the genomic stabil-
ity by governing the faithful segregation of chromosomes
[3–5].
Breast cancer is the single most common malignancy
in women [6]. Towards identifying novel regulators of
cell cycle in hMECs, we previously screened for binding
partners of the dominant hMEC-immortalizing onco-
gene HPV16 E6 and identified ADA3 as an E6-binding
protein [7], then showed it’s coactivator function for p53
[7, 8], retinoic acid receptor [9] and estrogen receptors
(ER) [10, 11]; other investigators showed its role in
androgen receptor [12]. We observed in breast cancer
cells that ADA3 was in a large complex that included
counterparts of the yeast SAGA complex (Ada2, Ada3
and Gcn5, a HAT), as well as the cell cycle- and cancer-
associated HATs, p300 and PCAF [11]. We also
demonstrated that ADA3 is essential for p300-mediated
p53 acetylation [8]. Together, these studies suggested a
potentially important role of ADA3 in breast cancer.
To explore the physiological roles of ADA3, we engi-
neered Ada3fl/fl mice and used these to show that germ-
line homozygous deletion of Ada3 was early embryonic
lethal [4]. The most dramatic result of conditional dele-
tion of Ada3 in Ada3fl/fl MEFs was defects in cell cycle
progression, including delayed G1 to S transition, mi-
totic catastrophe, and defective cytokinesis [4], suggest-
ing lack of coordination between DNA replication and
subsequent cytokinesis, a precursor for accumulation of
DNA damage and genomic instability [13]. Indeed,
Ada3-null MEFs exhibited increased basal levels of DNA
damage response, a delay in the repair of γ-irradiation-
induced DNA damage, and increased chromosomal
aberrations that increased further upon DNA damage
[3], suggesting critical roles of ADA3-dependent histone
acetylation in cell cycle-associated transcription, chro-
matin assembly around newly-synthesized DNA, reso-
lution of stalled replication forks and replication-
coupled DNA damage repair [14, 15]. Loss of Ada3 in
MEFs was associated with markedly reduced acetylation
of core histones, and reduced levels of p300 and PCAF
[4]. Another study using RNAi knockdown showed a
role of ADA3 in G2/M progression [16]. Together, these
studies demonstrate an essential role of ADA3 incell cycle progression in MEFs and in tumor cell lines
[3, 7–11].
Further studies from our laboratory examined the
expression of ADA3 in over 900 breast cancer tissue
specimens [17] with known clinico-pathological pa-
rameters and survival data. We showed that ADA3
was predominantly nuclear in ER+ breast cancers,
consistent with our previous studies that ADA3 func-
tions as an ER coactivator [10, 11], whereas ADA3
expression was both nuclear and cytoplasmic in ER-
breast cancers and this expression pattern correlated
with high ErbB2/EGFR status and predicted poor
patient survival [17].
In this study, we first confirmed our previous stud-
ies in Ada3fl/fl MEFs using immortal hMECs where
ADA3 depletion led to delayed cell cycle progression
with increased p27 and decreased SKP2 levels. Next,
we examined the consequence of ADA3 overexpres-
sion in immortal hMECs, as well as in ER+ breast
cancer cell lines. ADA3 overexpression in both ER-
immortal hMECs as well as in ER+ breast cancer cell
lines dramatically enhanced cellular proliferation. Cell
cycle analyses of ADA3 transfectants showed in-
creased cyclin B, c-MYC and SKP2 levels and
decreased p27 levels, findings opposite to those with
ADA3 knockdown. Furthermore, ADA3 overexpres-
sion led to increase in mRNA levels of early response
genes c-FOS, EGR1 and c-MYC. Analysis of a large
cohort of 588 breast cancer tissue specimens showed
a significant correlation of ADA3 nuclear expression
with c-MYC expression. Furthermore, combinatorial
expression of ADA3 and c-MYC showed significant
correlation with tumor grade, mitosis, pleomorphism,
Nottingham Prognostic Index (NPI), ER/PR status,
Ki67 and p27 expression. Multivariate cox regression
analysis of the whole cohort or the ER+ subgroups
showed significant correlation with tumor grade,
stage, and size. Finally, Kaplan Meier analysis showed
c-MYC and ADA3 to be independent markers of
poor survival as c-MYC high and ADA3 low status




76 N-TERT and 81 N-TERT, two immortalized human
mammary epithelial cell lines, were grown in DFCI-1
medium, as described earlier [18, 19]. MCF-7 and ZR-
75-1 cell lines were grown in α-MEM supplemented
with 10% fetal calf serum. For estradiol starvation and
stimulation experiments, MCF-7 and ZR-75-1 cell lines
were deprived in phenol red-free α-MEM medium
(ThermoFisher Scientific, Waltham, MA, USA) supple-
mented with 5% charcoal stripped fetal calf serum
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stimulated with 1nM β-estradiol (Sigma, St. Louis, MO,
USA) for synchronization experiments [11].Antibodies
Generation of anti-ADA3 mouse monoclonal antiserum
has been described previously [4]. Antibodies against
SKP2 (sc-7164), ERα, Hsc70 (sc-7298), PARP, and β-
actin were purchased from Santa Cruz Biotechnology;
p27 (610241) and Cyclin B1 (554179) from BD Biosci-
ences; c-MYC (ab32072) from Abcam, Inc; Ki-67 (Clone
MIB-1) from Dako. GAPDH (#2118) was obtained from
Cell Signaling. H3 (06-755), and H3K56 (07-677) anti-
bodies were from Millipore.Generation of Stable Ada3 shRNA Knock-down Cells and
ADA3 overexpressing cells
The hAda3-specific RNA sequence used in shRNA
constructs is GCAATCAGAACAAGCCCTT and the
scrambled shRNA is ACTACGCCTACAGTACGAA [8].
The oligonucleotides were cloned in the pSUPER-Retro
vector (OligoEngine, Seattle, WA). 76 N-TERT cells were
infected with shRNA retroviral supernatants, as de-
scribed previously [8]. Virally transduced cells were
selected in 0.5 μg/ml puromycin for 3 days, and expres-
sion of endogenous ADA3 was assessed in the whole cell
lysate using Western blotting with an anti-ADA3 mono-
clonal antibody [4]. The overexpression construct
encoding hADA3 isoform 1 (UniPort KB-075528) was
generated by PCR using oligonucleotides and cloning in
the pMSCV-Retro vector. 76 N-TERT cells were infected
with hADA3 retroviral supernatants, as described above
with shRNA infection. Virally transduced cells were
selected in 0.5 μg/ml puromycin for 3 days, and expres-
sion of endogenous ADA3 was assessed in the whole cell
lysate using Western blotting with anti-ADA3 antibody.
As an additional approach ADA3 was depleted by using
siRNA (sc-7846) and control siRNA (sc-37007) pur-
chased from Santa Cruz Biotechnology, using the same
protocol as described in reference [5].Cell cycle analysis
76 N-TERT cells expressing scrambled control shRNA
or ADA3 shRNA were synchronized in G1 phase of cell
cycle using growth factor deprivation by culturing in
DFCI-3 medium [18, 19] for 72 hrs, and then released
from G1 by switching to growth factor-containing
DFCI-1 medium. Cells were collected at 0, 8, 12, 14, 16,
20 and 24-hour time points and then processed for
FACS-based cell cycle analysis after propidium iodide
staining.Proliferation assays
To assess proliferation, cells were plated in 6-well plates
in triplicates at a density of 1.0 × 104 cells per well.
Trypan blue dye-excluding live Cells were counted on
alternate days using a hemocytometer.
RNA Extraction and Quantitative Real-time PCR
TRIzol reagent (ThermoFisher Scientific, Waltham, MA)
was used to isolate total RNA from cells. 2 μg of total
RNA was used for reverse transcriptase reaction using
SuperScriptTM II reverse transcriptase (Invitrogen).
Real-time PCR quantification was performed in tripli-
cates using SYBR Green PCR master mix (Applied
Biosystems) and the following primer sets: 1.c-fos -
Forward: GGGGCAAGGTGGAACAGTTATC, Reverse:
TAGTTGGTCTGTCTCCGCTTGG; 2. EGR1 - Forward:
ACCTGACCGCAGAGTCTTTTCC, Reverse: CAGGG
AAAAGCGGCCAGTATAG; 3. c-Myc - Forward: TCA
AGAGGCGAACACACAAC, Reverse: GGCCTTTTCA
TTGTTTTCCA; 4. β-actin - Forward: ATCGTCCACC
GCAAATGCTTCTA, Reverse: AGCCATGCCAATCT
CATCTTGTT The results were calculated by the ΔΔCt
method and presented as relative expression after
normalization against β-actin.
Analysis of the p27 Protein Turnover
For analyzing p27 protein half-life in exponentially
growing cells, cells were treated with 25 μg/ml of
cycloheximide (Sigma, St. Louis, MO) and then har-
vested at the indicated time points. Total cell extracts
were prepared, and equivalent amounts were run on
SDS-PAGE and analyzed by Western blotting. The
intensity of p27 bands was quantified by densitometry
and normalized to β-actin using ImageJ software.
Percentage of normalized intensities were calculated and
then converted to log values at base 2 and plotted on
the Y axis against time of cycloheximide treatment,
represented on the X axis [4].
Nuclear and cytoplasmic fractionation
Nuclear and cytoplasmic fractionation was performed
using a commercial kit (ThermoFisher Scientific,
Waltham, MA) (78833). Nuclear and cytoplasmic ex-
tracts from equivalent numbers of starting cells were
run on SDS-PAGE and analyzed by western blotting.
PARP and GAPDH respectively were used as controls
for nuclear and cytoplasmic markers, respectively to
assess the purity of extracts.
Statistical analysis of ADA3 and c-MYC IHC expression
Immunohistochemistry (IHC) staining of ADA3 in breast
cancer tissues was carried out as described previously
(nuclear expression of >1% was considered positive) [17].
The high and low nuclear expression of ADA3 was
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staining intensity was similarly determined and presented
as MYC-low (negative/weak staining) or MYC-high (mod-
erate/strong staining). Accordingly, the ADA3 and c-MYC
co-expression patterns are presented as follows: ADA3-
Low/ c-MYCLow, ADA3High/c-MYCLow, ADA3Low/ c-
MYCHigh, and ADA3High/c-MYCHigh. Associations of
these combinatorial patterns with various clinico-
pathological as well as molecular markers were deter-
mined using the Statistical Package for Social Sciences
SPSS version 21 for Windows (Chicago, IL, USA). A p
value of less than 0.05 (two-tailed) was considered signifi-
cant. Cut-off values for the various biomarkers included in
this study were chosen before statistical analysis. Standard
cut-offs were used for established prognostic factors and
were same as previously published for the patient series
analyzed here [20]. Analysis of categorical variables was
performed with χ2 test. Survival curves were generated
using the Kaplan–Meier method with significance deter-
mined by the Log Rank test. Multivariate analysis was
performed using the Cox proportional hazard analysis. A
p value (two-sided) < of 0.05 was considered significant.
For IHC analysis of patient derived xenograft (PDX)
ER+ tumors sections of formalin-fixed and paraffin-
embedded tissue samples were obtained from University
of Utah and processed for ADA3, ERα and Ki-67 IHC
staining, as described previously [17]. These PDX tu-
mors were generated by Dr. Welm’s laboratory by trans-
planting a portion of a tumor obtained from a patient
directly into an immunocompromised mouse [21].
Karyotype analysis
76 N-TERT vector or ADA3 overexpressing cells were proc-
essed for karyotype analysis, as described previously [3].
Invasion and migration analysis
Cells were deprived of estrogen for 72 hrs by culture in
phenol red-free α-MEM medium supplemented with 5%
charcoal dextran-stripped fetal calf serum (Atlanta
Biologicals, Flowery Branch, GA, USA). The migration
assay was done using BD BioCoatTranswell chambers
(#354578). 5.0x103 cells in 500 μl of deprivation medium
was seeded on top of transwell inserts. Two hours later
700 μl of medium containing 1nM β-estradiol was added
to the bottom chamber to serve as the chemoattractant.
At the end of the assay, Non-migrated cells on the upper
surface of filters were removed by scraping with cheese
cloth. The cells at the bottom of inserts were stained
using the Hema 3 kit from Fisher (Waltham, WA) and
then cells were counted. Invasion assay was performed
using BD Matrigel invasion chambers (#354480). Cells
were plated, processed and counted similar to migration
assay Invasion and migration of ADA3 cells were nor-
malized with respect to vector controls.Anchorage-independent growth
2 x104 MCF-7 vector and ADA3 overexpressing cells
per well were plated in triplicates in 6-well plates in
2 ml of 0.3% agarose in α-MEM on the top of a bot-
tom layer of 2 ml of 0.6% agarose in α-MEM
medium. Cultures were fed every 2 days with 2 ml of
α-MEM medium. Twenty-one days after cell seeding,
the plates were fixed and stained with 0.05% crystal
violet in 25% methanol and colonies in 5 random
fields per well were counted.
Results
ADA3 is a nuclear protein in ER- immortal hMECs and in
ER+ breast cancer cell lines, and is overexpressed in some
ER+ breast cancer patient-derived xenografts (PDX)
We have shown that Ada3 deletion in mouse embryonic
fibroblasts (MEFs) leads to delay in cell cycle progres-
sion. Importantly, cytoplasmic ADA3 expression corre-
lates with poor prognosis and poor survival in ER-
breast cancer patients [4, 17]. In this study, we focused
on the role of nuclear ADA3 using ER- normal hMECs,
ER+ breast cancer cell lines and ER+ primary breast
tumor tissues.
We initially carried out western blotting of total ly-
sates of immortal hMECs and ER+ breast cancer cell
lines for ADA3 expression and found all of these cells
express ADA3 protein, albeit somewhat different
levels (Fig. 1a). Next, we performed immunofluores-
cence staining with anti-ADA3 antibody as well west-
ern blotting of nuclear versus cytoplasmic fractions of
these cell lines and found that ADA3 is exclusively
localized in the nucleus in both normal hMECs and
in ER+ breast cancer cell lines (Fig. 1b, c).
Overexpression of ADA3 in immortal hMECs enhances
proliferation and alters cell cycle regulatory proteins
We previously reported that conditional deletion of
Ada3 in Ada3fl/fl mouse embryonic fibroblasts (MEFs)
leads to defects in cell cycle progression, including
delayed G1 to S transition, mitotic catastrophe, and
defective cytokinesis [4]. When endogenous ADA3 was
depleted in immortal hMECs with retrovirally trans-
duced shRNA, we observed a delay in exit of G1-
arrested cells into cell cycle progression together with
accumulation of CDK inhibitor p27 and a decrease in
the levels of SKP2 (See Additional file 1: Figure S2),
supporting a role of ADA3 in hMEC proliferation akin
to that in MEFs.
Next, we overexpressed exogenous ADA3 in two ER-
immortal hMECs (76 N-TERT and 81 N-TERT) and
confirmed ADA3 overexpression using western blotting
(Fig. 2a). Immunofluorescence and biochemical fraction-
ation showed that overexpressed ADA3 is found in both
nucleus and cytoplasm (Additional file 1: Figure S3) in
Fig. 1 Nuclear localization of ADA3 in immortal and estrogen receptor positive breast cancer cell lines. a Western blot analysis of ADA3
expression in immortal hMECs (76 N-TERT, MCF10A) and ER+ breast cancer cell lines (MCF-7, T47D, ZR-75-1). b ADA3 immunofluorescence stain-
ing in MCF-7 and 76 N-TERT cell lines, DAPI was used for nuclear staining. c Nuclear and cytoplasmic fractions were prepared from normal mam-
mary epithelial cell (76 N), immortal mammary epithelial cells (76 N-TERT and MCF10A), and ER+ breast cancer cell lines (MCF-7, ZR-75-1). Protein
concentration was quantitated, equal amounts of protein were separated on SDS-PAGE gel and then expression of various protein was assessed
with indicated antibodies. PARP was used as a nuclear control, and GAPDH was used as a cytoplasm control
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parental cells.
To assess the impact of overexpressed ADA3 on cell
proliferation, we plated equal numbers of vector or ADA3
transduced hMECs (day 0) and then counted the trypan
blue-excluding live cells every other day. Notably, ADA3-
overexpressing immortal hMECs exhibited a significantly
higher rate of proliferation as compared to vector control
cells (Fig. 2b, c). However, ADA3 overexpression did not
lead to any chromosomal aberrations as assessed by
karyotype analyses (Additional file 1: Figure S4).
Given the impact of ADA3 overexpression on cell pro-
liferation, we compared the expression of cell cycle regu-
latory proteins in vector or ADA3 overexpressing
hMECs during cell cycle progression after G1 arrest.
Western blotting of lysates at various time periods dur-
ing cell cycle progression showed that ADA3 overex-
pressing cells exhibit a more rapid and higher levels of
Cyclin B protein accumulation (Fig. 2d). In contrast to
results of ADA3 knockdown (Additional file 1: FigureS2B), ADA3 overexpressing hMECs exhibited higher
levels of SKP2 and markedly reduced accumulation of
p27 during cell cycle progression (Fig. 2d & e). As
ADA3 knockout MEFs exhibit a prolonged p27 half-life
[4], we assessed the half-life of p27 in vector vs. ADA3
overexpressing hMECs. Cells were treated with cyclo-
heximide to block new protein synthesis (0 time point)
and lysates harvested at various time points were west-
ern blotted to assess p27 levels. Densitometric quantifi-
cation showed that the turnover of p27 is substantially
faster in ADA3-overexpressing cells compared to that in
vector controls (Fig. 2f, g). Treatment with proteasome
inhibitor MG132 led to recovery of p27 protein levels in
ADA3-overexpressing cells comparable to that in control
cells (compare 3 hour lanes with or without MG132)
(Fig. 2f, g). The p27 mRNA levels were not affected by
ADA3 overexpression (data not shown). Taken together,
our results suggest a key role of ADA3 regulation of p27
levels in promoting cell proliferation in hMECs, similar
to that seen in MEFs [4].
Fig. 2 Exogenous overexpression of ADA3 leads to increased proliferation. a Western blotting of cells overexpressing ADA3. V = vector. 76 N-TERT cell
line (b) or 81 N-TERT cell line (c) expressing an empty vector (V) or ADA3 were plated at a density of 1 × 104 and then counted using a hemocytometer
on alternate days to measure proliferation. d Western blotting of cell lysates from synchronized (0 time point) or cells released from synchrony (1-28
hours) were immunoblotted with indicated antibodies. β-actin was used as a loading control. e Western blotting of cell lysates from synchronized (0 time
point and indicated time points released from synchrony (1-24 hours) were immunoblotted with SKP2, ADA3 or β-actin (used as a loading control).
f p27 half-life analysis. 76 N-TERT cells expressing vector or overexpressing ADA3 were treated with cycloheximide, and then cells lysates at indicated time
points were immunoblotted with anti-p27 antibody. Last lane, 3 hour time point of cells were treated with MG132. g The intensity of p27 bands was
quantified by densitometry, normalized to β-actin using ImageJ software, and then plotted against the time of cycloheximide treatment
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enhances the induction of early response genes
Previous studies using MEFs have shown that ADA3
regulation of SKP2-p27 is mediated by increase in c-
MYC levels, we analyzed c-MYC levels in ADA3-
overexpressing vs. control hMECs. We observed a
significant increase in c-MYC levels in ADA3 over-
expressing cells (Fig. 3a). Given the change in c-MYC
protein levels, and previous findings that ADA3 as a part of
the STAGA complex enhances c-MYC transcription [4], we
used qPCR to compare the levels of mRNA for c-MYC and
two other early response genes, c-FOS and EGR1, in vector
vs. ADA3-overexpressing hMECs that were allowed to pro-
gress through cell cycle after G1-arrest by growth factor
deprivation. The mRNA levels of c-MYC, c-FOS and EGR1increased upon cell cycle exit in both control and ADA3-
overexpressing hMECs, peaking at 1 hour; however, ADA3
overexpressing cells expressed higher levels of all three
genes as compared to vector control cells, especially at the
peak time point (Fig. 3b, c). These results support the idea
that ADA3 promotes the expression of MYC and other
early response genes as part of its ability to promote
hMECs proliferation.
ADA3 overexpression promotes proliferation of ER+
breast cancer cell lines
Given the results presented above with hMECs, we assessed
if ADA3 overexpression in ER+ breast cancer cells also
impacts the level of cell proliferation. We obtained vector
control or retroviral ADA3 transductants of MCF-7 and
Fig. 3 ADA3 transcriptionally regulate early response genes. 76 N-TERT cells vector or ADA3 overexpressing were deprived of growth factors for
72 hours and then released from synchrony via growth factor stimulation. Cells were collected at the indicated time points and total RNA was
extracted for real time PCR analyses. Real time PCR analysis of c-myc (a), c-fos (b) and EGR1 (c) is shown
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nuclear-localized ADA3 at levels similar to those in im-
moral hMECs (Fig. 1a). Overexpression was confirmed
using western blotting (Fig. 4a). Similar to the results in im-
mortal hMECs (Fig. 2b), ADA3 overexpression in both ER+
breast cancer cell lines led to hyper-proliferation (Fig. 4b, c).
As ER+ breast cancer cell lines require estrogen for prolifer-
ation [22, 23], we assessed if ADA3 overexpression induced
estrogen independent proliferation in MCF-7 or ZR-75-1
cell lines. Comparison of cell proliferation in the absence or
presence of estrogen revealed that ADA3 overexpression
does not eliminate estrogen dependence (Additional file 1:
Figure S5). Taken together, our results demonstrate that
ADA3 overexpression promotes hyper-proliferation in both
immortal ER- hMECs and ER+ breast cancer cell lines.
ADA3 overexpression in immortal hMECs or ER+ breast
cancer cell lines does not alter cell invasion, migration or
anchorage independence
Aside from hyper-proliferation, tumorigenesis requires
other traits, such as tumor cells migration and invasion,which may not correlate with the proliferation state [24].
To assess if ADA3 overexpression impacts cell migration
or invasion, we compared vector control and ADA3
overexpressing ZR-75-1 cells in standard migration and
invasion assays using transwells with or without Matrigel
coating, respectively. No significant differences in
migration or invasion abilities were observed between
vector control and ADA3 overexpressing ZR-75-1 cells
(Additional file 1: Figure S6). Furthermore, soft agar colony
formation assays showed no differences in the level of
anchorage independent growth of control vs. ADA3 over-
expressing MCF-7 cells (data not shown). These results sup-
port the conclusion that ADA3 overexpression promotes
cell proliferation but does not alter cell migration, invasion
or anchorage independence of ER+ breast cancer cell lines.
In view of the impact of ADA3 overexpression on ER+
cell proliferation, we examined two available ER+ PDX
tumors by IHC to assess ADA3 expression. We observed
that one ER+ sample (HCI-003) expressed intermediate
levels of ADA3, while the second sample (HCI-011)
expressed high levels of ADA3. Concurrent IHC staining
Fig. 4 Exogenous overexpression of ADA3 leads to increased proliferation of ER+ breast cancer cell lines. a Western blotting of cell lysates from
MCF-7 and ZR-75-1 expressing vector or ADA3. MCF-7 (b) or ZR-75-1 (c) cell lines expressing an empty vector or ADA3 were plated at a density
of 1.0x104 cells and then cells were counted on alternate days using a hemocytometer to measure proliferation
Table 1 Significant association between Positive Nuclear
expression of ADA3 and c-MYC in unselected breast cancer
cases (n = 588 cases)
Parameter c-MYC Nuclear Expression Significance
ADA3 Nuclear Expression Low No (%) High No.(%) x2 p value
Low No(%) 172 (49.1) 178 (50.9) 23.79 <0.0001
High No(%) 69 (29.0) 169 (71.3)
ER+ samples for high and low ADA3 and c-MYC expression showed a statisti-
cally significant difference among four groups
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higher percentage of Ki67+ cells in ADA3 high PDX
sample vs. the ADA3 intermediate sample (Additional
file 1: Figure S1), prompting further analyses using tissue
microarrays derived from a large cohort of ER+ breast
cancer patients.
ADA3 is overexpressed in a subset of ER+ breast cancers,
and its overexpression positively correlates with
expression of c-MYC
c-MYC plays a key role in breast cancer [26, 27], with gene
amplification seen in approximately 15% cases [26] and its
overexpression associated with poor outcomes [26, 28, 29].
Given our results in cellular models above, we examined if
ADA3 overexpression in ER+ breast cancer patients corre-
lates with c-MYC expression using a large unselected cohort
of primary invasive breast cancer specimens that includes
various subtypes of breast cancer and in which c-MYC over-
expression is known to be significantly associated with poor
prognostic factors, including tumor grade and basal-like
breast cancer phenotype [30]. c-MYC was also observed to
be an independent predictor of a shorter distant metastases-
free survival in luminal A LN+ tumors treated withendocrine therapy within this cohort [30]. We have previ-
ously assessed the ADA3 expression in this cohort [17]. In
this study we used the available ADA3 and c-MYC expres-
sion data to assess if ADA3 and MYC expression correlates
with each other and whether their relative expression pat-
terns predict outcomes in ER+ breast cancer patients.
588 patient samples had informative data on both
nuclear ADA3 and c-MYC expression as examined by
IHC. Notably, statistically significant positive correlation
between c-MYC and ADA3 expression was observed
(Table 1). Combinatorial co-expression groups were gen-
erated taking nuclear ADA3 and c-MYC expression into
account: 172/588 (29.3%) were ADA3Low/c-MYCLow,
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(30.3%) were ADA3Low/c-MYCHigh, and 169/588
(28.7%) were ADA3High/c-MYCHigh. Comparing these
four groups within the whole unselected series (i.e. ER+
and ER- patient samples) for clinico-pathologicalTable 2 Relationship between nuclear ADA3 and nuclear c-MYC co-
the whole unselected invasive breast cancer series (n = 588 cases)




Patient age ≤50 66 (31.7)
>50 106 (28.0)
Menopausal Status Pre 66 (30.4)
Post 106 (28.6)
Tumor size ≤2 cm 96 (28.0)
>2 cm 76 (31.4)
Tumor grade 1 20 (23.5)
2 47 (25.3)
3 105 (33.3)
Tubules 1 5 (22.7)
2 47 (25.1)
3 116 (32.7)
Pleomorphism 1 1 (14.3)
2 57 (26.0)
3 110 (32.6)
Mitosis 1 43 (24.6)
2 30 (29.1)
3 95 (33.2)
Axillary nodal stage 1 93 (28.5)
2 57 (28.2)
3 22 (37.3)







Tumor type Invasive Ductal/NST 123 (34.6)





Tubular Mixed 20 (20.6)
Mixed NST & Lobular 4 (19.0)
Mixed NST &other special types 2 (25.0)
N = number of cases. c. = cytoplasmic, n. = nuclear expression. NST = No Special Ty
Analysis of all patient specimens from the unselected invasive breast cancer cohort
in the areas of tumor grade, pleomorphism, tubule formation, mitotic scores, NPI, a
The bold font indicate that the clinical correlation is statistically significant < 0.05parameters, breast cancer molecular subtype, and mo-
lecular biomarker expression revealed statistically
significant differences between the four groups with
respect to tumor grade, mitotic scores, nuclear pleo-
morphism, tubule formation, Nottingham Prognosticexpression groups and clinico-pathological parameters within











24 (11.5) 65 (31.1) 53 (25.5) 1.862 0.602
45 (11.9) 113 (29.8) 115 (30.3)
25 (11.5) 68 (31.3) 58 (26.7) 0.907 0.871
44 (11.9) 110 (29.7) 110 (29.7)
14 (12.0) 99 (28.9) 107 (31.2) 2.765 0.429
28 (11.6) 77 (31.8) 61 (25.2)
14 (16.6) 17 (20.0) 34 (40.0) 32.961 <0.001
18 (9.7) 48 (25.8) 73 (39.2)
37 (11.7) 112 (35.4) 62 (19.6)
7 (31.8) 5 (22.7) 5 (22.7) 13.345 0.037
21 (11.2) 59 (31.6) 60 (32.1)
35 (9.9) 107 (30.1) 97 (27.3)
1 (14.3) 3 (42.9) 2 (28.6) 29.138 <0.001
31 (14.2) 46 (21.0) 85 (38.8)
31 (9.2) 122 (36.2) 74 (22.0)
23 (13.1) 40 (22.9) 69 (39.4) 23.706 0.001
9 (8.7) 30 (29.1) 34 (33.0)
31 (10.8) 101 (35.3) 59 (20.6)
42 (12.9) 90 (27.6) 101 (31.0) 6.617 0.353
23 (11.4) 68 (33.7) 54 (26.7)
4 (6.8) 20 (33.9) 13 (22.0)
21 (13.5) 39 (4) 66 (25.0) 33.968 <0.001
40 (12.8) 88 (8.8) 81 (28.2)
8 (6.8) 50 (36) 21 (17.8)
52 (13.8) 103 (27.2) 117 (31.0) 10.624 0.014
16 (7.8) 75 (36.8) 49 (24.0)
39 (11.0) 120 (33.7) 74 (20.8) 61.858 <0.001
8 (13.8) 4 (6.9) 33 (56.9)
3 (16.7) 9 (50.0) 4 (22.2)
6 (30.0) 5 (25.0) 4 (20.0)
11 (11.3) 28 (28.9) 38 (39.2)
2 (9.5) 6 (28.6) 9 (42.9)
0 3 (37.5) 3 (37.5)
pe. NPI = Nottingham Prognostic Index
demonstrates a significant correlation between nuclear ADA3 and c-MYC levels
nd tumor type across the four groups
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logic tumor types (Table 2). Moreover, statistically sig-
nificant differences were observed between these groups
regarding ER status, PR status, HER2 status, molecular
subtype, Ki67 expression and p27 expression (Table 3).
Analysis of these groups of patterns of nuclear ADA3
and nuclear c-MYC co-expression within the ER+ tu-
mors only (432 cases) with various clinico-pathological
parameters and molecular markers showed a significant
association of ADA3/c-MYC co-expression with tumor
grade, nuclear pleomorphism, NPI, LVI, histologic tumor
type, and the expressions Ki67 and p27 (Table 4). Kaplan
Meier survival plots (Fig. 5a and b), (Additional file 1:
Table S2 and S3) showed that nuclear ADA3Low/c-
MYCHigh or nuclear ADA3High/c-MYCLow status pre-
dicted poor outcome in the whole series (A) and in ER+
tumors (B), consistent with our previous analyses that
cytoplasmic ADA3 is an independent predictor of poor
outcome [17]. Multivariate cox regression analysis for
predictors of breast cancer specific survival within the
whole cohort and ER+ positive cases showed that
ADA3/c-MYC co-expression is significantly associated
with patients’ outcome independently of tumor grade,
stage, size and ER status (Table 5). Taken together, these
results show that i) ADA3 overexpression is seen in a
subset of ER+ patients, ii) ADA3 overexpression
correlates with c-MYC overexpression, iii) ER+ breast can-
cers can be categorized into 4 groups ADA3Low/c-
MYCLow, ADA3High/c-MYCLow, ADA3Low/c-MYCHighTable 3 Relationship between nuclear ADA3 and nuclear c-MYC co-







ER Status Negative 59 (39.6) 12 (8
Positive 113 (26.0) 56 (1
PR Status Negative 78 (36.0) 25 (1
Positive 79 (23.7) 43 (1
HER2 Status* Negative 6 (54.5) 2 (18
Positive 132 (27.0) 55 (1
Molecular Subtype Luminal 99 (25.4) 49 (1
HER2 Positive 34 (40.0) 10 (1
Triple Negative 38 (36.2) 7 (6.
Ki67 labelling** Index Low 42 (23.0) 27 (1
High 83 (29.9) 30 (1
p27 Low 114 (38.8) 33(1
High 40 (16.7) 33 (1
*HER2 Status was assessed using American Society of Clinical Oncology/College of
Cancer and Equivocal (2+) HER2+ cases were confirmed by FISH/CISH. ** Ki67 label
guidelines 2013
Analysis within the whole unselected invasive breast cancer series with respect to r
a statistically significant correlation across the four groupsand ADA3High/c-MYCHigh, iv) these four subgroups
showed significant differences in their association with
biomarkers and tumors grade and patients’ outcomes,
and v) most importantly low nuclear ADA3 or c-
MYC High status independently predicts poor survival
in ER+ breast cancer patients.
Discussion
Precisely regulated cell cycle progression is essential for
embryonic development as well as adult tissue homeostasis
[31]. Coordination of cell cycle progression with chromo-
somal duplication maintains genomic stability, a critical
cancer-associated trait [1]. Accordingly, deregulated cell
cycle components have emerged as key biomarkers and
therapeutic targets in cancer [2]. Thus, a better understand-
ing of cell cycle machinery and its aberrations in cancer are
of fundamental importance in cell and cancer biology.
Here, we show that ADA3 promotes cell proliferation in
ER- immortal human mammary epithelial cells and ER+
breast cancer cells involving deregulation of cell cycle
associated proteins. Importantly, nuclear ADA3 and c-
MYC co-overexpression analyses define ER+ breast cancer
subsets in which overexpression of c-MYC or loss of nu-
clear ADA3 independently predict poor survival.
While previous analyses of ADA3 knockout MEFs
have implicated this protein in cell cycle progression [4]
and we have reported that ADA3 overexpression and
cytoplasmic localization in breast cancer patient speci-
mens specifies poor outcomes [17], the roles of nuclearexpression combinatorial phenotypic groups with molecular bio-














.1) 56 (37.6) 22 (14.8) 25.800 <0.001
2.9) 121 (27.9) 144 (33.2)
0.3) 74 (30.6) 56 (23.1) 12.803 0.005
2.9) 102 (30.5) 110 (32.9)
.2) 1 (9.1) 2 (18.2) 21.743 0.010
1.2) 152 (31.1) 150 (30.7)
2.6) 110 (28.3) 131 (33.7) 25.405 <0.001
1.8) 24 (28.2) 17 (20.0)
7) 43 (41.0) 17 (16.2)
4.8) 40 (21.9) 74 (40.4) 22.081 <0.001
0.8) 101 (36.3) 64 (23.0)
1.2) 89 (30.3) 58 (19.7) 38.276 <0.001
3.8) 77(32.1) 90 (37.5)
American Pathologists Guidelines Recommendations for HER2 Testing in Breast
ling index dichotomized at 14% according to St Galen consensus
eceptor status, molecular subtype, Ki67 labeling index, and p27 demonstrated
Table 4 Relationship between nuclear ADA3 and nuclear c-MYC co-expression groups with molecular biomarker status within ER+
tumors only (n = 432 cases)














Patient age ≤50 35 (26.3) 18 (13.5) 39 (29.3) 41(30.8) 0.469 0.936
>50 78 (26.0) 38 (12.7) 82 (27.3) 102 (34.0)
Menopausal Status Pre 35 (24.5) 19(13.3) 44 (30.8) 45 (31.5) 1.002 0.8011
Post 78 (26.9) 37 (12.8) 77 (26.6) 98 (33.8)
Tumor size ≤2 cm 65 (24.3) 34 (12.7) 74 (27.6) 95 (35.4) 1.968 0.579
>2 cm 48(29.3) 22 (13.4) 45 (27.4) 49 (29.9)
Tumor grade 1 18 (22.0) 14 (17.1) 17 (20.7) 33 (40.2) 15.477 0.017
2 44 (25.6) 16 (9.3) 44 (25.6) 68 (39.5)
3 51 (28.5) 26 (14.5) 59 (33.0) 43 (24.0)
Tubules 1 5 (22.7) 7 (31.8) 5 (22.7) 5 (22.7) 9.813 0.133
2 41 (25.2) 17 (10.4) 51 (31.3) 54 (33.1)
3 65 (28.1) 27 (11.7) 60 (26.0) 79 (34.2)
Pleomorphism 1 1 (14.3) 1 (14.3) 3 (42.9) 2 (28.6) 19.460 0.003
2 52 (24.9) 31 (14.8) 42 (20.1) 84 (40.2)
3 58 (29.1) 19 (9.5) 71 (35.7) 51 (25.6)
Mitosis 1 40 (24.0) 22 (13.2) 38 (22.8) 67 (40.1) 10.175 0.117
2 23 (25.3) 8 (8.8) 30 (33.0) 30 (33.0)
3 48 (30.4) 21 (13.3) 48 (30.4) 41 (25.9)
Axillary nodal stage 1 58 (24.6) 35 (14.8) 61 (25.8) 82 (34.7) 3.652 0.724
2 43 (26.7 17 (10.6) 50 (31.1) 51 (31.7)
3 12 (32.4) 4 (10.8) 10 (27.0) 11 (29.7)
NPI Good 27 (18.6) 20 (13.8) 37 (25.5) 61 (42.1) 15.643 0.016
Moderate 63 (29.3) 31(14.4) 56(26.0) 65(30.2)
Poor 23 (31.5) 5(6.8) 27 (37.0) 18 (24.7)
Lymphovascular Invasion
(LVI)
Negative 75 (26.2) 44 (15.4) 67(23.4) 100 (35.0) 11.090 0.011
Positive 37 (25.3) 12 (8.2) 54 (37.0) 43 (29.5)
Tumor type Invasive Ductal/NST 71 (31.0) 28 (12.2) 71 (31.0) 59 (25.8) 44.333 <0.001
Invasive Lobular 13 (22.4) 8 (13.8) 4 (6.9) 33 (56.9)
Medullary-like 0(0) 1(33.3) 2 (66.7) 0 (0)
Excellent Prognostic Special
types*
5 (26.3) 6 (31.6) 5 (26.3) 3 (15.8)
Tubular Mixed 16 (17.4) 11 (12.0) 28 (30.4) 37 (40.2)
Mixed NST & Lobular 4 (19.0) 2 (9.5) 6 (28.6) 9 (42.9)
Mixed NST &other special
types
2 (28.6) 0 3 (42.9) 2 (28.6)
Ki67 labelling Index Low 35 (23.0) 25 (14.8) 33 (21.9) 68 (40.4) 11.217 0.011
High 49 (29.9) 22 (10.8) 38 (36.3) 50 (23.0)
p27 Low 61 (35.5) 21 (12.2) 47 (27.3) 43 (25.0) 18.993 <0.001
High 37 (16.9) 32 (14.6) 67 (30.6) 83 (37.9)
N = number of cases. c. = cytoplasmic, n. = nuclear expression. NST = No Special Type. NPI = Nottingham Prognostic Index
Analysis of ER+ patient specimens with respect to tumor grade, nuclear pleomorphism, NPI, LVI, histologic tumor type, Ki67 labeling index, and P27 demonstrated
a statistically significant correlation across the four groups
The bold font indicate that the clinical correlation is statistically significant < 0.05
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Fig. 5 Kaplan Meier plots of nuclear ADA3 and nuclear c-MYC co-expression. Different combinatorial phenotypic groups were categorized;
ADA3Low/c-MYCLow; ADA3High/c-MYCLow; ADA3Low/c-MYCHigh; ADA3High/c-MYCHigh as indicated with different colors. a in the whole series of
breast cancer patients (n = 588 cases) with respect to breast cancer specific survival (BCSS) for 300 months b. Kaplan–Meier plot of nuclear ADA3 and
nuclear c-MYC co expression combinatorial phenotypic groups within ER + ve tumors only (n = 432 cases) breast cancer patients with respect to BCSS
Griffin et al. Breast Cancer Research  (2016) 18:113 Page 12 of 15ADA3 in epithelial cells and the importance of its over-
expression in ER+ breast cancer were not examined. In
this study, we used immortal (non-tumorigenic) hMECs
and ADA3 shRNA/siRNA-mediated knockdown and
ADA3 overexpression approaches to establish a clear
role of ADA3 in proliferation of ER- mammary epithelial
cells. Similar to Ada3 knockout in Ada3fl/fl MEFs [4],
knockdown of ADA3 in immortal hMECs led to delay in
cell cycle progression as seen by delay in G1 to S phase
transition, accumulation of p27 and decrease in SKP2
levels, suggesting that ADA3 operates in cell cycle pro-
gression in hMECs and MEFs by the same mechanism
[32–34]. Additionally, ADA3 regulates mitosis by its
association with CENP-B/centromere and regulates segrega-
tion of chromosomes to maintain genomic stability [5]. Re-
cently, we demonstrated that ADA3 is acetylated protein and
acetylation of ADA3 by its associated HATs is essential for
its key role in cell cycle progression [35].
Given that several cell cycle regulatory proteins are
upregulated in cancers to help maintain the higher
proliferation rates of cancer cells, we analyzed patient
derived xenograft tissue from two ER+ breast cancer
patients and noted substantially higher ADA3 levels in
one tumor specimen; interestingly, the higher ADA3
expression levels correlated with higher proportion ofTable 5 Multivariate cox regression analysis for predictors of breast
ER+ subgroups
Parameter In the whole cohort
P value HR
ADA3 combinatorial expression 0.040 1.0
Tumor grade 0.002 1.4
Tumor stage <0.001 2.1
Tumor size 0.015 1.1
ER status 0.971 0.1
HR: Hazard Ratio, CI: confidence intervalcells positive for Ki67, a marker of cell proliferation. The
suggestion from these experiments that overexpressed
ADA3 could drive increased proliferation in breast
cancer is supported by our analyses of ADA3 over-
expression in immortal hMECs, ER+ breast cancer cell
lines and correlative analyses in a large cohorts of ER+
breast cancers specimens.
While ADA3 knockdown/knockout significantly halted
cell cycle progression (Additional file 1: Figure S2),
overexpression of ADA3 significantly promoted cell
proliferation (Fig. 2). Notably, hyper-proliferation of
ADA3 overexpressing hMECs involved a more rapid
transit into cell cycle that was associated with increased
Cyclin B levels and downregulation of p27 protein due
to rapid turnover (Fig. 2d). Consistent with these
conclusions, increased SKP2 levels were seen in ADA3-
overexpressing hMECs (Fig. 2e). As our previous results
showed that ADA3 is important in cell cycle associated
c-MYC transcription [4], we assessed the c-MYC as well
as two other early response gene, c-FOS and EGR1, and
found that ADA3 overexpression increased the mRNA
levels of all three (Fig. 3). These results are consistent
with our previous findings where we defined ADA3-c-
MYC-SKP2-p27 pathway for role of ADA3 in cell cycle
regulation in MEFs. We and others have previouslycancer specific survival (BCSS) within the whole cohort and the
In ER+ only
(95% CI) P value HR (95% CI)
6 (1.01–1.16) 0.001 1.12 (1.05- 1.96)
4 (1.14 – 183) 0.001 1.49 (1.17 -1.90)
1 (1.73- 2.58) <0.001 2.21 (1.72- 2.84)
4 (1.07- 1.91) 0.069 1.38 (0.98 - 1.96)
0 (0.71- 1.39) - -
Griffin et al. Breast Cancer Research  (2016) 18:113 Page 13 of 15reported that ADA3, as part of STAGA complex, binds
to c-MYC enhancer elements [36, 37]. Notably, another
transcriptional coactivator, SRC3 has also been shown to
enhance cell proliferation when overexpressed [38].
However, we [11] and others have not observed
SRC3 to be present in ADA3-containing protein
complexes, suggesting that these co-activators pro-
mote cell proliferation through distinct mechanisms.
C-FOS is known to be important in promoting cell
proliferation and EGR1 is important for cell prolifer-
ation and migration [39–41]. Thus, elevated expres-
sion levels of these proteins could further contribute
to increased proliferation seen in ADA3 overexpress-
ing hMECs.
Given a vast body of literature linking c-MYC
expression to positive regulation of cell proliferation
[42–44] and our results that ADA3 regulates c-MYC
levels (Additional file 1: Figure S2), [3, 4], we assessed
the impact of overexpressing ADA3 in ER+ breast
cancer cell lines and then analyzed the relationship of
nuclear ADA3 and c-MYC expression in ER+ breast
cancer specimens. Interestingly, overexpression of
ADA3 induced hyperproliferation even in ER+ breast
cancer cell lines, suggesting that ADA3 protein over-
expression in certain ER+ tumors may increase prolif-
eration index. Analyses of a well characterized cohort
of breast cancer tissue samples for nuclear ADA3 and
c-MYC expression helped categorize breast cancers
into four groups; ADA3 Low/c-MYCLow, ADA3High/
c-MYCLow, ADA3Low/c-MYCHigh and ADA3High/c-
MYCHigh group of patients. Nuclear ADA3 and c-MYC
overexpression was positively correlated (Table 1), under-
scoring our experimental data in cellular systems that
ADA3 regulates c-MYC expression (Fig. 2) [3]. Compari-
son of combined ADA3/c-MYC expression with clinico-
pathological parameters showed a significant correlation
of the patterns of their co-expression with tumor grade,
pleomorphism, NPI status and tumor types, as well as ex-
pression of Ki67 and p27 proteins. Similar results were
seen when ADA3/c-MYC combinatorial expression was
explored in only the ER+ cases. Univariate and multi-
variate analyses showed that low nuclear ADA3 stain-
ing or high c-MYC expression independently predict
poor survival in ER+ breast cancers. While ADA3
overexpression correlated with c-MYC overexpression,
survival analyses showed that low ADA3 expression
serves as an independent marker for poor survival in
ER+ breast cancer patients. The association of low
nuclear ADA3 levels with poor survival, while some-
what counterintuitive, is consistent with our previous
analyses of this tissue cohort in which cytoplasmic
localization of ADA3 was found to be a poor prog-
nostic marker in non-ER+ breast cancers [17], It will
therefore be of considerable interest to dissect themolecular pathways by which cytoplasmic ADA3 con-
tributes to poor prognosis and poor survival.
Conclusions
We demonstrate: i) overexpression of ADA3 enhances
cell proliferation in immortal and tumor mammary
epithelial cells; ii) increased expression of ADA3 corre-
lates with overexpression of c-MYC; iii) ADA3 and c-
MYC expression categorize breast cancers into four
groups; ADA3Low/c-MYCLow, ADA3High/c-MYCLow,
ADA3Low/c-MYC High and ADA3High/c-MYCHigh;
iv) c-MYC High and ADA3 Low status independently
predicts poor survival in patients.
Additional file
Additional file 1: Figure S1. High ADA3 expression in patient derived
xenografts correlates with elevated Ki67. Are presentative of two ER+ /PR
+ tumor grafts from two different breast cancer patients (HCI-003 and
HCI-011). Patient-derived xenografts (as described in DeRose et al. [11])
were sectioned and stained with antibodies indicated (brown staining).
Blue staining is hematoxilin. Figure S2. Knockdown of ADA3 causes a
delay in cell cycle progression in immortal hMECs.76N-TERT cells express-
ing scrambled shRNAor Ada3 shRNAwere deprived of growth factors in
DFCI-3 media for 72hrs, then released from synchrony by adding growth
factor containing DFCI-1 medium. Cells were then collected at the
indicated time points for various analyses. (A) FACS analysis after propidiu-
miodide staining. Cell cycle profile (G1/S/G2/M) at selected time points
is shown (B) Lysates were immunoblotted with indicated antibodies.
β-actin was used as a loading control. (C) Lysates from 76N-TERT transfected
with ctrl. or ADA3 siRNA were immunoblotted with indicated antibodies.
Figure S3. Exogenous overexpression of ADA3 in Human Mammary
Epithelial Cells. Endogenous expression of ADA3 in 76N-TERT cells is only
nuclear but after over expression of ADA3, expression is observed in both
nucleus and cytoplasm. (A) 76N-TERT.V (i and ii) or 76N-TERT. ADA3 cells
(iii and iv) stained for ADA3. (B) ADA3 protein levels after biochemical fraction-
ation, PARP and α-tubulin are used as nuclear and cytoplasmic control,
respectively. Figure S4. ADA3 over expression does not alter chromosomal
stability. A) Representative karyotype of 76N-TERT vector cells and B) represen-
tative karyotype of 76N-TERT ADA3 cells. Figure S5. ADA3 overexpression
does not induce estrogen independence for proliferation. Indicated cell lines
overexpressing vector (V) or ADA3 were deprived of estrogen in phenol red-
free alpha-MEM medium supplemented with 5% charcoal dextran stripped
fetal calf serum for 72hrs and stimulated with 1nM of β-estradiol. Fresh
medium was added on alternate days and total number of cells were
determined using a hemocytometer and trypan blue exclusion method.
Figure S6. ADA3 overexpression has no effect on invasion or migration of
cells. ZR-75-1, a ER+ breast cancer cell line expressing vector (V) or ADA3 was
examined for changes in invasive (A) or migratory (B) potential using Boyden
chamber method. Table S1. Karyotypicanalysis of 76N-TERT vector or ADA3
overexpressing cell lines. Table S2. Survival analysis in the whole cohort.
Table S3. Survival analysis in the ER+ cohort Only. (PDF 575 kb)
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